Related Experiment Video

Updated: Dec 16, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.9K

miR-100-5p Inhibits Malignant Behavior of Chordoma Cells by Targeting IGF1R

Hongliang Zhang1,2, Kang Yang3, Tingting Ren1,2

  • 1Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China.

Cancer Management and Research
|July 2, 2020
PubMed
Abstract

Insights

MicroRNA-100-5p is downregulated in chordoma. Restoring miR-100-5p levels suppresses chordoma growth and metastasis by targeting the insulin-like growth factor 1 receptor (IGF1R).

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Chordoma is a rare bone tumor with limited treatment options.
  • Understanding the molecular mechanisms driving chordoma progression is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of microRNA-100-5p (miR-100-5p) in chordoma.
  • To elucidate the underlying molecular mechanism of miR-100-5p in chordoma pathogenesis.

Main Methods:

  • MicroRNA array analysis and qRT-PCR to assess miR-100-5p expression in chordoma tissues.
  • In vitro assays (cell proliferation, Transwell, flow cytometry) to evaluate miR-100-5p function.
  • Bioinformatic prediction, dual-luciferase assays, and Western blot to validate IGF1R as a direct target of miR-100-5p.

Main Results:

  • miR-100-5p was significantly downregulated in chordoma tissues compared to normal tissues.
  • Overexpression of miR-100-5p inhibited chordoma cell proliferation, migration, and invasion, partly by suppressing epithelial-mesenchymal transition (EMT).
  • Insulin-like growth factor 1 receptor (IGF1R) was confirmed as a direct target of miR-100-5p and was overexpressed in chordoma tissues.

Conclusions:

  • miR-100-5p acts as a tumor suppressor in chordoma.
  • The miR-100-5p/IGF1R axis plays a critical role in chordoma progression.
  • Targeting miR-100-5p or its downstream effectors may offer a novel therapeutic strategy for chordoma.
Keywords:
IGF1RchordomamiR-100-5pmiRNA

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K